Our efforts are concerned with identifying features of incomplete malignant transformation caused by non viral pathogens. Theileria parva (T. parva) is a tick-transmitted protozoan parasite that can cause a fatal lymphoproliferative disease in cattle. The T. parva-infected lymphocytes display a transformed phenotype and 
Introduction
Members of the genus Theileria are intracellular apicomplexan protozoan parasites transmitted by ticks. Among several Theileria species, T. parva is highly pathogenic for cattle and cause fatal lymphoproliferative diseases known as East Coast fever (Brown et al., 1973; Irvin et al., 1975; Lawrence and 1987) . The MDM2 protein acts as a negative regulator of p53 through two known mechanisms: First, MDM2 binds p53 through its NH2-terminus, resulting in inhibition of its transcriptional activity (Momand et al., 1992) , and second, the COOH-terminus of MDM2 serves as an E3 ubiquitin ligase targeting p53 for proteasomal degradation (Haupt et al., 1997) . MDM2 can exhibit oncogenic activity when overexpressed in cells (Fakharzadeh et al., 1991) , and gene amplification and overexpression of MDM2 protein are found in about 10% of human tumors (Toledo and Wahl, 2006) . In addition, many spliced isoforms of MDM2 are observed in human tumors, and the cDNA coding some of these spliced isoforms is also capable of transforming cells (Sigalas et al., 1996) . Thus, both overexpression and alternative splicing of MDM2 are thought to contribute to its oncogenic function.
In this study, we screened T. parva-infected lymphocytes for susceptibility to a library of compounds with known anti mitotic activity in an attempt to identify signaling pathways involved in causing parasite-induced unlimited cell proliferation.
TIBC is an anticancer agent that has been suggested to affect the MDM2/p53 protein complex to selectively inhibit the growth of MDM2-overexpressing tumors (Kumar et al., 2003) . The anti-tumor effects of
RT-PCR for detection of spliced isoforms of mdm2
Total RNA was isolated from cells by the PureLink Micro-to-Midi Total RNA Purification System (Invitrogen). cDNAs were then synthesized from total RNA in the presence of oligo(dT) primers using a Ready-To-Go You-Prime First-Strand Beads kit (GE Healthcare) in accordance with the manufacturer's instructions. The resulting cDNAs were used in nested PCR to detect mdm2. Nested PCR primers were designed based on the bovine mdm2 sequence, mdm2F1 (5'-AACTGGGGAGCCTCGGGGGA-3') and mdm2R1
(5'-GGTATTATCTTGCTTTGATACACCT-3') for the first amplification, and mdm2F2
(5'-GTTAGTGAGCATCAGGCAAATGTG-3') and mdm2R2 (5-TTACAGGTAGTTCAACTAGGGG-3') for the second amplification. Each PCR was performed under the following conditions: 95˚C for 1 min, 25
amplification cycles (95˚C for 1 min, 55˚C for 1 min, and 72˚C for 1 min), and a final extension step (72˚C for 7 min). As an internal control, GAPDH amplification was performed with BoGAPDH-F (5'-TTCAACGGCACAGTCAAGG-3') and BoGAPDH-R (5'-ACATACTCAGCACCAGCATCAC-3'), using the conditions described above, except for the annealing temperature, which was 57˚C. Amplification of the mdm2b isoform was also performed using specific primers (BoMBforward:
5'-AAGAGACCCTGGACTATTGGAAGTG-3' and BoMBreverse:
5'-TGCCATTGAACCTTGTGTGATTTG-3') after a first amplification with mdm2F1 and mdm2R1, as previously described (Steinman et al., 2004) . For mdm2b isoform detection, a 30 amplification cycle was used while the rest of the PCR protocol remained the same as above. The PCR products were resolved on 1.2% agarose gels, isolated, cloned into the pGEM-T Easy Vector system (Promega), and sequenced in an ABI Prism 3700 Analyzer (Applied Biosystems).
Quantitative RT-PCR
The levels of transcription of mdm2 and p53 were determined by quantitative RT-PCR with SYBR Premix Ex Taq (Takara) and Eva Green dye (Biotium). Values were normalized to the value of GAPDH. Primer sequences were as follows; MDM2: 5'-GGCATGCTTCACATGTGCAA-3' and 5'-GTACAATCATTTGAATTGGTTGCC-3'; p53: 5'-ACTGGAAGACTCTTGTGGTAACCT-3' and 5'-TTTTCTTCCTCAGTGCGGCGGTC-3'; GAPDH: 5'-GGTCATCATCTCTGCACCTTCTG-3' and 5'-AGGGTGTTGTTATACTTCTCGTGG-3'. Standard curves were constructed for all amplicons and each measurement was performed in triplicate. The reaction was performed at 95˚C for 10 s, followed by 40 amplification cycles (95˚C for 10 s, 60˚C for 20 s) in a Mx3000P Real-Time PCR System (Stratagene).
Western blot analysis
Whole cell extracts were lysed in a lysis buffer (0.5% TritonX-100, 50 mM Tris-HCl [pH7.4], 150 mM NaCl) supplemented with a protease inhibitor cocktail (Complete Mini; Boehringer Mannheim) at 4˚C for 10 min, and centrifuged. Supernatants were resuspended in a sample buffer for sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and heated at 100˚C for 3 min. The concentrations of the proteins were estimated using the BCA Protein Assay Reagent (Thermo Scientific) or Quant-iT Protein Assay kit (Invitrogen). Proteins from each sample (30 g) were subjected to electrophoresis in a polyacrylamide gel, and separated proteins were transferred to a sheet of PVDF membrane (Bio-Rad Laboratories). The filters were blocked in 5% skim milk powder in Tris-buffered saline with 0.1% Tween 20 (TBS-T) for 1 h at room temperature, and washed with TBS-T three times for 10 min each. The filters were incubated with primary antibodies overnight at 4˚C, washed, and incubated for 1 h at room temperature with horseradish peroxidase-conjugated goat anti-mouse antibody (Zymed laboratories, cat. no. 62-6420; 1:3,000) or goat anti-rabbit antibody (Jackson ImmunoResearch, cat. no. 111-036-045; 1:6,000). The bands were visualized with SuperSignal West Femto Maximum sensitivity substrate (Thermo Scientific). Membranes were reprobed with another antibody after they were stripped with Restore Western Blot Stripping Buffer (Thermo Scientific).
Antibodies used in this study were anti-MDM2 (N20; 1:1,000; Santa Cruz), anti-p53 (PAb421; 1:1,000;
Merck-Calbiochem), anti-Bax (Poly6251; 1:3,000; BioLegend), and anti--actin (C4;1:3,000; Santa Cruz Biotechnology).
Immunostaining
For staining of MDM2, cytospin smears of T. parva-infected cells (G6TpM) were fixed with 4%
paraformaldehyde/PBS at room temperature for 15 min, permeabilized with 0.2% Triton X-100 for 10 min and blocked with 5% skimmed milk for 1 h, before staining with anti-MDM2 (N20 diluted 1:500) for 1 h at room temperature followed by Alexa 594-conjugated anti-rabbit Ig (Invitrogen). Immunostaining for p53 was performed essentially as described by Haller et. al. (Haller et al., 2010) . The slides were fixed with 3% paraformaldehyde/PBS for 10 min, permeabilized with 0.25% Triton X-100 for 10 min, blocked with 10% bovine serum albumin in PBS for 30 min, stained with anti-p53 (OP33, Calbiochem; 1:2000) overnight at 4˚C, and detected with Alexa 555-conjugated anti-mouse Ig (Invitrogen). DAPI (blue) was used for nuclear staining.
Reporter assay
To determine p53 activity in the cells, 5×10 5 T. parva-infected cells (G6TpM) and BTL-26 cells in 24-well plates were co-transfected with 500 ng of a p21 luciferase reporter plasmid (Shimizu et al., 2002 ) and a control plasmid containing Renilla luciferase pGL4.70 (25 ng; Promega). After 12 h, cisplatin or TIBC was added to the culture, and cells were incubated for an additional 24 h. Transfection was performed with the Neon Transfection System (Invitrogen) at 1300 V, 30 ms pulse width and one-time pulse. These conditions were optimized to achieve high levels of efficiency and viability (data not shown). Both firefly and Renilla luciferase activity was assayed with the Dual-Luciferase Reporter Assay System (Promega) and measured with a GloMax luminometer (Promega). The firefly signal was normalized using the Renilla luminescence signal.
Results

Identification of signaling pathway related to proliferation of T. parva-infected lymphocytes
We examined the effects of various chemical inhibitors using the SCADS inhibitor kits I and II, which consist of 190 inhibitors. In the first screening, 65 compounds were found to inhibit proliferation of T. The MDM2 inhibitor TIBC specifically induce apoptosis in T. parva-infected lymphocytes MDM2 is well-recognized oncoprotein that participates in the induction of malignant lymphoma when overexpressed in mice (Jones et al., 1998) . MDM2 has not previously been studied in T. parva infection.
The ability of the MDM2 inhibitor TIBC to induce apoptosis of T. parva-infected lymphocytes was examined.
The T. parva-infected and non-infected cell lines used in this study are summarized in Table 2 .
T. parva-infected
G6TpM cells displayed susceptibility to TIBC at high concentrations, exhibiting high levels of apoptosis, whereas the bovine leukemia cell line BTL-26 and MDBK cell line remained unaffected (Fig. 1A) . The effects of TIBC on other T. parva-infected cells, including a different stock of T. parva (Marikebuni stock) and uninfected bovine lymphocytic cells (listed in Table 2 ) were further investigated. As shown in Fig. 1B , T.
parva-infected cell lines (011TPM and 951-E43TPMa) were highly susceptible for TIBC induced apoptosis.
Discernible pathologic effects were not observed in non-infected cells (951ConA) at the concentration used in the experiment. These results suggest that MDM2 participates in maintaining the immortalization of T.
parva-infected lymphocytes.
Isolation of spliced mdm2 isoforms from T. parva-infected lymphocytes
The complete coding region of bovine mdm2 was isolated from a cDNA obtained from T.
parva-infected G6TpM cells by nested RT-PCR ( Fig. 2A) . The bovine MDM2 amino acid sequence predicted from the resultant cDNA sequence showed 94% amino acid identity with human MDM2 (HDM2; GenBank accession number NM_002392; Fig. 3A) . Analysis of the mdm2 PCR products from T. parva-infected lymphocytes revealed several shorter products in addition to an increased amount of the product corresponding to the full-length transcript (Full-mdm2), whereas no such changes to the amplification were observed in ConA cell lines 641 and 951, BTL-26 and MDBK cells ( Fig. 2A) . Cloning and sequencing of these RT-PCR products from T. parva-infected G6TpM cells led to identification of 4 alternatively spliced isoforms of mdm2 transcripts from T. parva-infected lymphocytes, which were designated mdm2-TPalpha (GU951438), mdm2-TPFL7
(GU323559), mdm2-R3U (GU323560), and mdm2-TPR3L (GU323561). Two of these corresponded to transcripts described previously in other species (Fig. 3A) : Mdm2-TPalpha contained an insert of 87 bp between exon 4 and 5, and this additional sequence contained a stop codon in-frame. This transcript corresponds to mdm2 identified from PBMC in human and dog (Veldhoen et al., 1999) and to mdm2-DS3 obtained from a soft tissue sarcoma (Bartel et al., 2001 ). This alpha domain sequence and the insertion sites found to be highly conserved between the human, canine, and bovine products (Fig. 3A) . The mdm2-TPalpha sequence is predicted to disrupt the p53 binding domain of the MDM2 protein. The second splice variant, mdm2-TPFL7, in which exon 5 was aberrantly spliced to exon 12, corresponds to mdm2-FB28 identified in pediatric rhabdomyosarcoma (Bartel et al., 2001 ). In the two novel alternatively spliced transcripts of MDM2, mdm2-TPR3U and mdm2-TPR3L, exon 4 was aberrantly spliced to exon 12. Mdm2-TPFL7 and mdm2-TPR3L caused a frame shift in the region encoding the C-terminus, resulting in completely new predicted amino acid sequences and loss of the RING domains, whereas mdm2-TPR3U and mdm2-TPalpha retain these domains. Because mdm2b (HSU33200) is the most commonly found spliced isoform of mdm2 in numerous types of cancer cells (Bartel et al., 2002) , and it can induce cell transformation independently of p53 (Steinman et al., 2004) , we examined transcription of bovine mdm2b by nested RT-PCR using mdm2b-specific primers, as described previously (Steinman et al., 2004) . The mdm2b transcript is aberrantly spliced from exon 3 to exon 12. mdm2b transcripts were detected in T. parva-infected cell lines tested, but only a faint band were detected in uninfected ConA-stimulated lymphocytes ( Fig. 2B ), suggesting that an elevation of mdm2b mRNA levels is associated with
MDM2 is overexpressed in cells infected with T. parva
MDM2 is overexpressed in various tumors, and TIBC and nutlin-3 are effective at inhibiting the growth of MDM2-overexpressing cells, such as breast cancer cells (Kumar et al., 2003) , glioma cells (Sasayama et al., 2007) , and human pediatric acute lymphoblastic leukemia cells (Gu et al., 2008) . The finding that T.
parva-infected lymphocytes are sensitive to MDM2 inhibitors led us to investigate protein expression levels of MDM2. We performed Western blot analysis with anti-MDM2 antibody (N20) and found that T. parva-infected cells had increased MDM2 levels, compared to ConA-stimulated lymphocytes (Fig. 4A ). As observed for sensitivity to TIBC, the expression levels of MDM2 varied depending on the parasitized cell line examined. The highest expression level of MDM2 was observed in the 592TPM cell line (T. parva -infected B cell line). Since
Theileria infection does not always result in the same patterns of host cell signaling pathway activation in cell lines of different phenotype (Guergnon et al., 2003; Rocchi et al., 2006) , this variation in expression levels of MDM2 may be due to difference in host cell phenotype and/or the parasite species or strain. Elimination of the parasite by treatment with the theilericidal drug buparvaquone led to the disappearance of the MDM2 bands ( 
p53 accumulation in response to DNA damage is disordered in T. parva-infected lymphocytes
Cisplatin binds to DNA and forms platinum-DNA adducts, resulting in p53 accumulation and induction of apoptosis (Siddik, 2003) . To examine p53 protein activity in T. parva-infected lymphocytes, expression in T. parva-infected and uninfected cell lines prior to and/or after (24h) treatment with cisplatin was compared by Western blot analysis. In both uninfected cell lines (BTL-26, MDBK cells), the levels of p53 increased after treatment with cisplatin, whereas the T. parva-infected cells (G6TpM) showed no apparent accumulation of p53 protein following cisplatin-treatment (Fig. 5A ). The transcription levels of p53 were also determined by quantitative RT-PCR in T. parva-infected cells (G6TpM), BTL-26 cells, and MDBK cells after treatment with cisplatin. Transcription of p53 was further upregulated in the T. parva-infected cells by the cisplatin treatment, but was unaffected in the two uninfected cell lines (Fig. 5B ). In addition, p21-luciferase reporter assay indicated that p53 activities after cisplatin treatment in T. parva-infected cells remained unaffected despite those in control BTL-26 cells increased in dose dependent manner (Fig. 5C) , consistent with the results of Western blot analysis in Fig. 5a . These observations indicate that p53 protein accumulation and activity is impaired in T. parva-infected lymphocytes.
TIBC restores the p53 response in T. parva-infected lymphocytes
To determine whether impairment of p53 accumulation was associated with MDM2 overexpression, we examined the status of p53 after treatment with TIBC. Western blot analysis showed an increased level of p53 protein after 24 h of exposure to TIBC in T. parva-infected cells (G6TpM). Expression of the pro-apoptotic molecule Bax, a p53 target, was also elevated in G6TpM cells (Fig. 5D ), indicating that the p53 pathway remained functional in T. parva-infected lymphocytes and could be restored by inhibiting MDM2 activity.
Consistent with the restoration of p53 protein, increased p53 activity in TIBC-treated T. parva-infected G6TpM cells was also confirmed using a p21-reporter plasmid assay as shown in Fig. 5C .
Nuclear accumulation of p53 were induced by TIBC treatment
Activation of p53 is accompanied by its stabilization and nuclear accumulation by MDM2. To determine cellular the distribution of p53 after abrogation of MDM2 function, T. parva-infected cells were stained with anti-p53 before and after treatment of TIBC for 48 h. While untreated cells showed undetectable levels of p53 protein, TIBC treatment for 48 h lead to the accumulation of p53 in nucleus, most likely in the nucleoli (Fig. 6A ). On the other hand, MDM2 were distributed mainly in the nucleoplasm (Fig. 6B upper) .
Disappearance of MDM2 staining signals in the cells which showed typical apoptotic morphological changes of nucleus (arrowhead) after induction of apoptosis by theilericidal drug buparvaquone were observed, indicating that the expression of MDM2 is regulated by the presence of the parasite.
Discussion
Transformation features of T. parva-infected lymphocytes are sensitive to the MDM2 inhibitor TIBC.
Infected cells express high levels of MDM2 and have several alternatively spliced mdm2 transcripts. The overexpression of MDM2 protein in T. parva-infected cells was associated with enhanced transcription or increased stability of mdm2 mRNA as demonstrated by real-time RT-PCR. MDM2 is an oncoprotein that controls tumorigenesis through both p53-dependent and p53-independent mechanisms (Bartel et al., 2002) . It is known that the p53-dependent mechanism involves inhibition of p53 activity by MDM2, by direct-binding (Momand et al., 1992) , shuttling p53 from the nucleus to the cytoplasm (Tao and Levine, 1999) , and inducing ubiquitination and hence degradation by the ubiquitin-proteasome system (Haupt et al., 1997) . Several lines of evidence support a role for p53-independent functions of MDM2 in tumor formation (Bouska et al., 2008; Ganguli and Wasylyk, 2003) .
p53 is a major regulator of cell homeostasis in response to insults such as radiation damage, microbial infection, or tumorigenesis (del Aguila et al., 2006; Teodoro and Branton, 1997; Vousden and Lu, 2002) . Oncogenes that deliver strong mitogenic signals cause cellular senescence that arrests cell proliferation or causes apoptosis by the p53-dependent pathway (Yaswen and Campisi, 2007) . Because Theileria infection results in strong mitogenic stimulation and the majority of infected cells retain wild-type p53, activation of p53 might be expected to retard proliferation and allow elimination of the infected cells. However, T. parva-infected cells acquire the ability to proliferate indefinitely, avoiding cell-cycle arrest and apoptosis. Indeed, a recent study by Haller et al. (2010) demonstrated that p53-mediated host cell apoptosis is suppressed during Theileria infection, but is rapidly re-activated after elimination of the parasite by the anti-parasitic drug treatment (Haller et al., 2010) . Notably, we detected an mRNA in T. parva-infected lymphocytes predicted to encoding a protein homologous to mdm2b, which has been reported to have p53-independent tumorigenicity (Steinman et al., 2004) .
Among 5 spliced isoforms of mdm2 detected in T. parva-infected lymphocytes, three of them corresponded to previously reported spliced isoform sequences of mdm2 (mdm2-TP2b corresponded to human mdm2b, mdm2-TP corresponded to human mdm2, and mdm2-TPFL7 corresponded to mdm2-FB28 from human rhabdomyosarcoma), whereas the other two isoforms (mdm2-TPR3U and mdm2-TPR3L) were novel. The predicted protein products of all of them lacked the p53-binding domain, but mdm2-TP, mdm2-TPR3U, and mdm2-TP2b still bore the RING finger domain at the C-terminus. The C-terminal RING finger domain of MDM2 contains a cysteine residue that is essential for its function as an E3 ubiquitin conjugating enzyme and for its ability to induce degradation of p53 (Honda and Yasuda, 2000) . We did not determine whether these spliced isoforms of mdm2 were expressed as protein species, but we speculate that one or more of the isoforms play some role of incomplete transformation of T. parva-infected cells by p53-independent mechanisms.
Alternatively, expression of spliced isoforms of mdm2 may merely be a secondary phenomenon associated with excess transcription of mdm2, because spliced forms of mdm2 mRNA were usually found together with full-length MDM2 transcripts (Bartel et al., 2002) .
Upon DNA damage, p53-MDM2 interactions are affected by phosphorylation of p53 (Bode and Dong, 2004) . Indeed, in our study, p53 protein was increased after cisplatin treatment in control cells (BTL-26 or MDBK) without an increase in p53 mRNA transcription, suggesting that p53 levels in these cells were post-transcriptionaly controlled by MDM2 preventing the degradation of p53. In contrast, T. parva-infected lymphocytes were not responsive to cisplatin-induced p53 accumulation. We noted that p53 mRNA was upregulated, suggesting that the absence of p53 accumulation is post-transcriptionally controlled, either by translation failure or excessive degradation, rather than the result of a reduced transcription rate. Since MDM2 was aberrantly overexpressed in T. parva-infected cells, active degradation of p53 may be the most likely explanation for the defective p53 response. The enhanced transcription of p53 may be caused by MDM2, which induces p53 translation as a negative feedback loop (Wu X Fau -Bayle et al., 1993) . To test the hypothesis that the p53 dysfunction was caused by aberrant MDM2 expression, we examined the status of p53 after treatment with a MDM2 inhibitor. Indeed, the MDM2 inhibitor TIBC rescued normal p53 accumulation with transcriptional function, and caused apoptosis of the T. parva-infected lymphocytes, suggesting that over-expression of MDM2 contributed to the perturbation of the p53 pathway.
In our studies, p53 was mainly localized within the nucleus of the infected cells, and the staining signal for p53 in the nucleus was increased after TIBC treatment (Fig. 6A ). Other workers have reported that p53 in T. parva-infected cells is associated with the schizont membrane (Haller et al., 2010) In T. parva-infected cells, MDM2 was primarily localized to the host nucleoplasm (Fig. 6B) . In untransformed cells, p14 ARF -/p19 ARF negatively regulates MDM2 by sequestering MDM2 from the nucleoplasm to nucleoli, which results in the accumulation of p53 in the nucleoplasm (Weber et al., 1999) . The observed nucleoplasmic localization of MDM2 in the T. parva-infected cells might be linked indirectly to altered ARF function by the infection.
. The molecules known to regulate the transcription of mdm2 include p53 (Juven et al., 1993) , AP-1, Ets (Phelps et al., 2003) , and PTEN (Chang et al., 2004 ). The nuclear factor-kappa B (NF-B) is also a transcription regulator of MDM2 through its binding to the P1 promoter, and has been shown to induce MDM2 expression in mouse embryonic fibroblasts (Tergaonkar et al., 2002) and activated T cells (Busuttil et al., 2010) .
Inhibition of the multi-subunit I kappa B kinase suppresses MDM2 expression levels in Epstein Barr
virus-infected cells, suggesting that the steady-state protein level of MDM2 can be controlled by NF-B activity (Forte and Luftig, 2009) . NF-B is constitutively activated in T. parva-infected lymphocytes as a consequence of modulation of multi-subunit IB kinase signalosome complex Heussler et al., 2002; Ivanov et al., 1989) . Hence, NF-B activation may be a key step for constitutive upregulation of MDM2 in T.
In addition to NF-B activation, the phosphoinositide 3-kinase (PI3-K)/Akt pathway may be relevant to functional activation of MDM2. Phosphorylation of MDM2 by Akt/PKB has been reported to result in nuclear translocation of MDM2 (Mayo and Donner, 2001 ), enhancement of MDM2-mediated ubiquitination of p53 (Ogawara et al., 2002) , and stabilization of MDM2 by preventing self-ubiquitination (Feng et al., 2004) .
Intriguingly, the PI3-K/Akt pathway is also known to be constitutively activated in T. parva-infected cells (Heussler et al., 2001a) . Thus, constitutive activation of both the NF-B and the PI3-K/Akt pathway could favor survival of parasitized cells by promoting MDM2 expression and enhancing its function, as well as stimulating the expression of anti-apoptotic and pro-proliferative genes (Dobbelaere et al., 2000; Dobbelaere and Kuenzi, 2004; Shiels et al., 2006) .
Our results indicate that enhanced expression of MDM2 in T. parva-infected cells alters p53 stabilization. These results document a mechanism by which incomplete transformation of cells occurs as a consequence of pathogenic infection by protozoa.
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